Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Clin Cancer Res. 2021 Sep 15;27(23):6405–6412. doi: 10.1158/1078-0432.CCR-21-1579

Figure 1. The IGFBP-2 N-terminus vaccine was immunogenic and selectively generated Th1 but not Th2 immunity.

Figure 1.

Mean (±SEM) corrected spots per well (cSPW) in 1x106 PBMC for (A) IFN-γ or (B) IL-10. Mean (±SEM) percent (C) Tbet+CD4+ or (D) Tbet+CD8+. Lines connect values from each patient determined pre-treatment (0) and at the maximum response (Max). n=20 patients; *p<0.05, **p<0.01.